Elliott Earns 13% On Pharma. Deal

Jan 30 2014 | 11:25am ET

Elliott Management pushed pharmaceutical company McKesson Corp. to boost its offer for drug distributor Celesio by just 2.1%, but still made a 13% return on the deal.

According to Market Securities' Timothee de Mierry, the hedge fund accomplished the feat with a side-deal to sell its convertible bonds to McKesson. Elliott, which owned a nearly 25% stake in Celesio, dropped its opposition to McKesson's deal after the company increased its offer by €0.50 per share—and agreed to buy Elliott's convertible bonds. After faltering earlier this month, the deal was finalized last week.

McKesson did not initially disclose how much it paid for the convertibles, but did so in a regulatory filing later.

"We estimate the see-through price is about €30, so they made €165 million altogether on their convertible holding," de Mierry told Reuters.

Elliott accomplished the feat in spite of the fact that it bought most of its Celesio shares at or above McKesson's original offer price. The hedge fund has agreed not to buy any Celesio or McKesson securities or to oppose their boards for five years, and will not seek to disrupt the merger any further, the McKesson filing said.


In Depth

Q&A: TCA Fund Management's Bob Press on Small-Cap Private Equity

Aug 25 2016 | 8:55pm ET

The emergence of private credit as a replacement for traditional bank financing...

Lifestyle

Kiawah: Island Reversal

Aug 24 2016 | 9:59pm ET

Looking for real estate investments but the typical real estate fare isn’t cutting...

Guest Contributor

Old Hill Partners: Embrace Illiquidity

Aug 9 2016 | 2:39pm ET

The age-old financial concept that higher yields are the result of higher risk and...